**Core Concept:** Nuchal translucency (NT) is a screening tool used to measure the thickness of the fluid-filled space at the back of the neck in an early fetal ultrasound scan. It is a marker for Down syndrome (trisomy 21) risk assessment.

**Why the Correct Answer is Right:** Nuchal translucency is an important part of prenatal screening for Down syndrome, Turner syndrome, and other chromosomal abnormalities. A higher NT measurement is associated with an increased risk of these conditions due to the presence of excessive amounts of amniotic fluid in the fetal neck. This measurement is usually performed between 11 to 14 weeks of gestation, and if the result is elevated, further testing, such as chorionic villus sampling (CVS) or amniocentesis, is recommended to confirm the diagnosis.

**Why Each Wrong Option is Incorrect:**

A. This option is incorrect because nuchal translucency is specifically used for Down syndrome risk assessment rather than general fetal wellbeing monitoring.

B. This option is incorrect because nuchal translucency is not used to assess structural abnormalities in the fetus, but rather, chromosomal abnormalities.

C. This option is incorrect because nuchal translucency is not used for assessing fetal heart function; echocardiography is the appropriate test for evaluating fetal cardiovascular system.

D. This option is incorrect because nuchal translucency is used for chromosomal abnormalities assessment, not for determining fetal sex. A karyotype analysis is required for sex determination.

**Clinical Pearl:**

Understanding the role of nuchal translucency in prenatal screening is crucial for healthcare professionals as it helps them identify high-risk pregnancies and recommend appropriate further testing to ensure proper management and intervention for affected fetuses.

**Correct Answer:** C. Nuchal translucency is used for assessing fetal chromosomal abnormalities, specifically to evaluate the risk of trisomies (e.g., Down syndrome, Turner syndrome).